Table 1. Patient characteristics.
| No. of patients | WIP1 High | WIP1 Low | |
|---|---|---|---|
| Age (years) | |||
| <3 | 3 | 2 | 1 |
| 3-18 | 37 | 20 | 17 |
| >18 | 24 | 10 | 14 |
| Gender | |||
| Male | 39 | 17 | 22 |
| Female | 25 | 15 | 10 |
| Chang stage | |||
| M0 | 45 | 18 | 28 |
| M1 | 5 | 2 | 3 |
| M2 | 4 | 4 | 0 |
| M3 | 9 | 8 | 1 |
| No information | 1 | 0 | 0 |
| Molecular subtype | |||
| WNT-activated | 16 | 0 | 16 |
| SHH-activated | 20 | 8 | 12 |
| Group 3 | 8 | 7 | 1 |
| Group 4 | 20 | 19 | 1 |
| 17q status | |||
| Copy number gain | 29 | 26 | 3 |
| Total | 64 |
WIP1 high versus low expression is based on median WIP1 expression. Age refers to age at diagnosis. Chang staging refers to published criteria for staging of medulloblastoma metastasis. Molecular subtyping was determined using unsupervised clustering approaches. Copy number status of 17q was determined using array-based comparative genomic hybridization. Abbreviations: WNT, wingless; SHH, sonic hedgehog; 17q, long arm of chromosome 17.